TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Autism Spectrum Disorder~Exclusion Criteria:~none

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Test arm (Type: None): The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
- Control arm (Type: None): The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 16.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years or greater~* Living in a zip code classified as a Small and Isolated Small Rural Town area by Rural-Urban Commuting Area Codes (RUCAs), and/or in a county classified as rural based on RUCAs, and/or in a county with a score of .4 or higher on the index of relative rurality (IRR)~* Living in Alabama, Arkansas, Georgia, Kentucky, Mississippi, Missouri, Oklahoma, South Carolina, or Tennessee~* Living with HIV~* Indicates willingness to participate in support groups~* Indicates willingness to self-collect a dried blood spot sample~* Has a telephone at home~* Able to provide informed consent~Exclusion Criteria:~* Not meeting eligibility criteria described above

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Social Support + Stigma Reduction + SBCM + Tech Detailing (Type: EXPERIMENTAL): None
- Social Support + Stigma Reduction + SBCM (Type: EXPERIMENTAL): None
- Social Support + Stigma Reduction + Technology Detailing (Type: EXPERIMENTAL): None
- Social Support + Stigma Reduction (Type: EXPERIMENTAL): None
- Social Support + SBCM + Technology Detailing (Type: EXPERIMENTAL): None
- Social Support + SBCM (Type: EXPERIMENTAL): None
- Social Support + Technology Detailing (Type: EXPERIMENTAL): None
- Social Support (Type: EXPERIMENTAL): None
- Stigma Reduction + SBCM + Technology Detailing (Type: EXPERIMENTAL): None
- Stigma Reduction + SBCM (Type: EXPERIMENTAL): None
- Stigma Reduction + Technology Detailing (Type: EXPERIMENTAL): None
- Stigma Reduction (Type: EXPERIMENTAL): None
- SBCM + Technology Detailing (Type: EXPERIMENTAL): None
- SBCM (Type: EXPERIMENTAL): None
- Technology Detailing (Type: EXPERIMENTAL): None
- HIV Information Only (Type: NO_INTERVENTION): This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed recurrent high grade serous ovarian cancer or triple negative breast cancer~* Subjects with recurrent, metastatic triple negative breast cancer must have had at least 1 chemotherapy regimen for metastatic breast cancer or have developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy~* Prior therapy for high grade serous ovarian cancer subjects must have included a first-line platinum-based regimen~* At least 4 weeks since prior radiation therapy, 3 weeks since prior chemotherapy and 6 weeks if the last regimen included BCNU or mitomycin C~* At least 4 weeks since any small-molecular kinase inhibitors or any other type of investigational agent~* Life expectancy of at least 4 months~* Able to swallow and tolerate oral medications~Exclusion Criteria:~* Evidence of bowel obstruction, abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of study entry~* Current dependency on IV hydration or total parental nutrition~* Diabetes mellitus unless well controlled~* Pregnant or breast feeding~* History of grade 3 or 4 toxicities with previous PI3kinase inhibitor or PARP inhibitor~* Current or active dermatologic diagnoses that would preclude interpretation of skin toxicities of BKM120~* Receiving any medications or substances that are strong inhibitors or inducers of CYP3A4~* History of cardiac dysfunction or disease~* Persistent toxicities (greater than or equal to CTCAE grade 2) caused by previous cancer therapy~* Major surgery within 14 days of starting study treatment~* Evidence of coagulopathy or bleeding diathesis~* History of major depressive episode, bipolar disorder, obsessive/compulsive disorder, schizophrenia, history of suicide attempt or ideation or homicide/homicidal ideation~* CTCAE grade 3 or greater anxiety~* Uncontrolled, intercurrent illness~* Known HIV positive and on combination antiretroviral therapy~* Receiving chronic treatment with steroids or another immunosuppressive agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm BKM (Type: EXPERIMENTAL): BKM120 and Olaparib
- Arm BYL (Type: EXPERIMENTAL): BYL719 and Olaparib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* seasonal allergic rhinitis with or without allergic conjunctivitis~* sensitization to grass pollen allergens (confirmed with skin prick tests, conjunctival provocation test, specific IgE)~* symptoms of allergic rhinitis with or without conjunctivitis for at least 2 years before the study~Exclusion Criteria:~* sensitization to allergens, that could interfere with grass pollen~* asthma~* cystic fibrosis~* ciliary dysmotility syndrome~* bronchiectasis~* smoking~* tuberculosis~* neoplastic disease~* chronic sinusitis and nasal polyps~* systemic glucocorticosteroids treatment~* treatment with immunotherapy in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): 20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
- Specific subcutaneous immunotherapy (Type: ACTIVE_COMPARATOR): 21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Postmenopausal women with osteoporosis (Lumbar spine or femoral neck BMD or total hip T-score less than or equal to-2.5)~Exclusion Criteria:~1. Women with vertebral (L1-L4) abnormalities that preclude accurate measurement by DEXA.~2. Women on medications that are known to affect bone for more than 7 days in the past 6 months.~3. Currently taking systemic prednisone, inhaled steroids, anticoagulants, anticonvulsants.~4. History of rhPTH use or known hypersensitivity to study drug.~5. Vitamin D3 deficiency (Vitamin D3 \< 20 ng/ml).~6. Abnormal thyroid function.~7. History of kidney disease.~8. Any history of hypercalciuria, hypercalcemia or hyperparathyroidism.~9. History of active or treated tuberculosis or significant liver disease or gastrointestinal disease or cancer.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Drug Group (Type: EXPERIMENTAL): Osteoform
- Control group (Type: ACTIVE_COMPARATOR): SHELCAL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of familial adenomatous polyposis with at least 5 rectal polyps which are greater than or equal to 2 mm on baseline colonoscopy~* Have an endoscopically assessable rectal segment~* Have not taken NSAIDs or selective COX-2 inhibitors for two months prior to the study and willing to remain off NSAIDs for the study duration.~Exclusion Criteria:~* Known allergies or hypersensitivity to berries~* Diabetes mellitus~* Subjects taking NSAIDs or COX-2 inhibitors who cannot be taken off the medication due to their clinical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Black Raspberry (BRB) Slurry plus BRB suppositories (Type: EXPERIMENTAL): 20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
- Black Raspberry (BRB) Placebo Slurry plus BRB suppositories (Type: EXPERIMENTAL): 20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be \> 24 months and \< 30 years of age when registered on study.~* Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than a partial response to standard treatment or persistent neuroblastoma that had at least a partial response to frontline therapy frontline therapy with \> 3 residual lesions on end-induction MIBG scan.~* Patients must have evidence of MIBG uptake into tumor at ≥ one site within 4 weeks prior to entry on study and subsequent to any intervening therapy.~* Patients must have adequate heart, kidney, liver and bone marrow function. Patients who have bone marrow disease must still have adequate bone marrow function to enter the study.~* Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable CD34+ cells/kg available.~Exclusion Criteria:~* They have had previous I-131 MIBG therapy~* They have other medical problems that could get much worse with this treatment.~* They are pregnant or breast feeding.~* They have a history of a venous or arterial thrombosis that was not associated to a central line.~* They have active infections such as hepatitis or fungal infections.~* They have active diarrhea.~* They have had an allogeneic stem cell transplant (received stem cell from someone else)~* They can't cooperate with the special precautions that are needed for this trial.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Single-Agent 131I-MIBG (Type: ACTIVE_COMPARATOR): Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
- 131I-MIBG with Vincristine/Irinotecan (Type: ACTIVE_COMPARATOR): Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
- 131I-MIBG with Vorinostat (Type: ACTIVE_COMPARATOR): Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any self-declared ethno-racial category.~* Medically healthy subjects.~* Subjects with two healthy eyes.~* Intraocular pressure (IOP) less than 22 mmHg in each eye.~* Best-corrected visual acuity (BCVA) in each eye 20/50 or better.~* Open angles in both eyes.~* Contact lens wear stopped at least 3 days prior to study, and during the study.~* Ability to cooperate for examinations required for study.~Exclusion Criteria:~* Chronic or acute ophthalmic diseases including glaucoma, wet type macular degeneration, uveitis and clinically significant cataract.~* Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis.~* Cornea pathologic changes preventing reliable measurement.~* Narrow anterior chamber angle.~* Previous intraocular surgeries, laser procedures, and intravitreal injections.~* Previous corneal refractive surgeries.~* Myopia greater than -6.00 D spherical equivalent.~* Hyperopia greater than +2.00 D spherical equivalent.~* Lack of suitable episcleral vein for measurement.~* Ocular trauma within the past 6 months.~* Ocular infection or ocular inflammation in the past 3 months.~* Ocular medication of any kind within 30 days of study visit.~* Known hypersensitivity to Phenylephrine or topical anesthetic medication.~* Severe hypertension: Systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 105 mmHg.~* A known history of ischemic heart disease (angina or myocardial infarction), cerebrovascular accidents, cardiac arrhythmias, cerebral or aortic aneurysms.~* Uncontrolled diabetes mellitus.~* Uncontrolled hyperthyroidism.~* Use of some systemic medications within 30 days prior to study including: β-adrenergic antagonists, α-adrenergic agonists and antagonists, calcium channel blockers, diuretics, vasodilators, monoamine oxidase inhibitors, and systemic steroids.~* Participation in any interventional study within the past 30 days prior to study visit.~* Women who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Phenylephrine (Type: EXPERIMENTAL): Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- Is in generally good health and is scheduled to have a total knee replacement~Exclusion Criteria:~* Is allergic, intolerant to, or has a history of a significant clinical or laboratory adverse experience associated with etoricoxib or other cyclooxygenase-2 (COX-2) inhibitors/non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, morphine, or oxycodone, or has hypersensitivity to aspirin, or other NSAIDs~* Has uncontrolled hypertension~* Is currently a user of any illicit drugs, or has a history of drug or alcohol abuse within the past 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etoricoxib 90 mg (Type: EXPERIMENTAL): Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
- Etoricoxib 120 mg (Type: EXPERIMENTAL): Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
- Ibuprofen 1800 mg (Type: ACTIVE_COMPARATOR): Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HAE~* Normal C1q level~Exclusion Criteria:~* Low C1q level~* B-cell malignancy~* Presence of anti-C1INH autoantibody~* History of allergic reaction to C1INH or other blood products~* Narcotic addiction~* Current participation in any other investigational drug study or within the past 30 days~* Participation in a C1 esterase inhibitor trial, or received blood or a blood product in the past 90 days~* Pregnancy or lactation~* Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1INH-nf (Type: EXPERIMENTAL): 1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of mild asthma, currently well controlled requiring only a bronchodilator (e.g. salbutamol) as needed and infrequently~* has allergies that trigger asthma~* responds to methacholine challenge at 16mg/ml or less~* has FEV1 \> 69.5% predicted~Exclusion Criteria:~* respiratory illness within 4 weeks~* other medical condition assessed by the principal investigator that would put the participant at risk or influence the integrity of the data~* pregnant or lactating females~* hypersensitivity to ibuprofen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen (Type: EXPERIMENTAL): 400mg (2X200mg) ibuprofen single dose once
- Placebo (Type: PLACEBO_COMPARATOR): identical appearing lactose capsules single dose 2 capsules once

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete